Jones Trading Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $11
Benzinga Newsdesk 7 months ago
NewsPrice TargetInitiationAnalyst Ratings
Jones Trading analyst Debanjana Chatterjee initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Buy rating and announces Price Target of $11.
Jones Trading analyst Debanjana Chatterjee initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Buy rating and announces Price Target of $11.